PTO/SB/80 (11-08)
Approved for use through 11/30/2011. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

1 h a sa h	voke all previous powers of attorney	given in the appli	cation identified in the a	ttached statement under	
37 CFR 3.	73(b).	9.70.1			
I hereby a	opoint:				
Practitioners associated with the Customer Number: <i>OR</i>			86738		
Practit	ioner(s) named below (if more than ten paten	t practitioners are to be	e named, then a customer nun	nber must be used):	
Name		Registration	Registration Name		
		Number		Number	
			D (1 - 1 T-c 1 1 Off	(I ISPTO) in connection with	
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents					
attached to t	his form in accordance with 37 CFR 3.73(b).				
Please chan	ge the correspondence address for the applic	cation identified in the	attached statement under 37 C	JFR 3.73(D) to:	
The address associated with Customer Number:					
OR '"	e address associated was occurre, warmen				
Firm	or Elizabeth A. Hanley, Esq.	. McCarter & Eng	lish, LLP		
individual Name					
200 Transant outcor		State		Zip	
City	Boston	MA		02110	
Country	USA				
Telephone	617-449-6510		Email ehanley@mccarter.com		
Assignee N	ame and Address:				
7 Trinity	erapeutics Limited Street				
London,	Jnited Kingdom SE1 1DA				
i					
A convo	this form, together with a statement	under 37 CFR 3.73	(b) (Form PTO/SB/96 or e	quivalent) is required to be	
filed in ea	this form, together with a statement ch application in which this form is u	sed. The statemer	nt under 37 CFR 3.73(b) n	nay be completed by one of n hehalf of the assignee.	
	ich application in which this form is u tioners appointed in this form if the a Identify the application in which this	populied practitivi	ICI 12 GOTILOLIFOR IN HALL		
and must					
	SIG The individual whose signature and t	NATURE of Assigned itle is supplied below	is authorized to act on behalf	of the assignee	
0	Vita Scan		Date 2	2 nd September 2009	
Signature	hundrager Lucy Bodget		Telep	hone +44 (0)1625 518739	
Name	Lucy Padget				
Title	Authorised Signatory n of information is required by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 and 1.33 are considered by 37 CFR 1.31, 1.32 are considered by 37 CFR 1.31 are considere	and 1.33. The information	is required to obtain or retain a be	enefit by the public which is to file (an	
This collection	n of information is required by 37 OFK 1.31, 1.32 of	mod by 35 H S C 122 ar	nd 37 CFR 1.11 and 1.14. This coll	ection is estimated to take 3 minutes t	

Inis collection or information is required by 37 CFL 131, 132 and 133. The line 133 Term 134 Term 135 Collection is estimated to take 3 minutes to by the USPTO to process) an application. Confidentiality is governed by 35 U.S. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to by the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, and submitted to take 3 minutes to the USPTO. Time will vary depending upon the individual case. Any complete including gathering, and submitted to take 3 minutes to the USPTO. Time will vary depending upon the individual case. Any complete including the complete dapplication form to the USPTO. Time wi

PTO/SB/96 (06-09)

Approved for use through 07/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)					
Applicant/Patent Owner: Arrow Therapeutics Limited					
Application No./Patent No.: 10/593,666 Filed/Issue Date: March 12, 2007 Entitled: PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN					
Arrow Therapeutics Limited , a corporation					
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)					
states that it is:					
the assignee of the entire right, title, and interest in;					
 an assignee of less than the entire right, title and interest in (The extent (by percentage) of its ownership interest is%); or 	an assignee of less than the entire right, title and interest in (The extent (by percentage) of its ownership interest is%); or				
the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)					
in the patent application/patent identified above by virtue of either:					
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel Frame DO25, or for which a copy thereof is attached.					
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:					
1. From:To:					
The document was recorded in the United States Patent and Trademark Office at					
Reel, Frame, or for which a copy thereof is attached.					
2. From:To:					
The document was recorded in the United States Patent and Trademan	rk Office at				
Reel, Frame, or for which a copy thereof is attached.					
3. From:To:					
The document was recorded in the United States Patent and Tradema	rk Office at				
Reel, Frame, or for which a copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sheet(s).					
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.					
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]					
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.					
<u>xuestadact</u>	2" September 2009				
Signature					
Lucy Padget	Authorised Signatory				
Printed or Typed Name	Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

